RAN and neuroblastoma: Higher expression of survivin and Ran conveys a significant poorer prognosis in patients of high and low risk, as determined by copy number of MYCN (Fig. 1C), stage (Fig. 1D) and age (Fig. 1E), except for survivin in tumors with MYCN amplification (Fig. 1C). Taken together, these data show the importance of the survivin-Ran nexus in NB.